AbbVie Gets FDA Expanded OK of Skyrizi in Crohn's Disease
June 17 2022 - 8:47AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Friday said the U.S. Food and Drug Administration
approved the expanded use of its blockbuster psoriasis drug Skyrizi
in adults with moderately to severely active Crohn's disease.
The North Chicago, Ill., biopharmaceutical company said Skyrizi
is the first new treatment option in six years for moderately to
severely active Crohn's, a chronic inflammatory bowel disease.
AbbVie reported worldwide Skyrizi revenue topping $2.9 billion
last year and has said it expects risk-adjusted sales of more than
$7.5 billion for the drug in 2025.
Skyrizi, which is part of a collaboration between AbbVie and
German pharmaceutical company Boehringer Ingelheim GmbH, was
previously approved to treat moderate to severe plaque psoriasis
and active psoriatic arthritis in adults.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 17, 2022 08:32 ET (12:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024